Trademark Overview
On Friday, August 11, 2023, a trademark application was filed for KAMAU THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the KAMAU THERAPEUTICS trademark a serial number of 98128117. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 8, 2024. This trademark is owned by Kamau Therapeutics, Inc.. The KAMAU THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations in the nature of genetically modified cells for use in the treatment of genetic diseases and disorders; pharmaceutical preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for gene therapy, gene editing, genome editing, and targeted gene replacement and insertion; cell therapy products in the nature of genetically modified cells for the treatment of genetic diseases and disorders; gene therapy products in the nature of genetically engineered human genes for the treatment of genetic diseases and disorders; pharmaceutical preparations for non-genotoxic conditioning to enable engraftment; pharmaceutical preparations containing templates of DNA sequences to restore and normalize the function in a disease-causing gene; gene edited and corrected human cells for medical use
Pharmaceutical research and development services; Research in the fields of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; research and development of therapeutics pharmaceuticals using gene editing; providing medical and scientific research information in the field of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; research in the field of clustered regularly interspaced short palindromic repeats (CRISPR) and homology directed repair (HDR) technologies
